PMV Pharmaceuticals PMVP 深 沪
已收盘 11-13 16:00:00 美东时间
1.27
+0.060
+4.96%
华盛通- 最 高1.27
- 今 开1.22
- 成交量 29.08万股
- 最 低 1.19
- 昨 收 1.21
- 总市值 9592.91万
- 52周最高 1.91
- 市盈率 静 --
- 换手率 0.39%
- 52周最低 1.02
- 委 比 0.90%
- 总股本 7553.47万
- 历史最高 63.22
- 量 比 0.99
- 振 幅 6.61%
- 历史最低 0.81
- 每 手 1
- 风险率 0.15%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多PMV Pharma Q3 EPS $(0.52) Misses $(0.34) Estimate
PMV Pharma (NASDAQ:PMVP) reported quarterly losses of $(0.52) per share which missed the analyst consensus estimate of $(0.34) by 52.94 percent. This is a 30 percent decrease over losses of $(0.40) per share from the same period last year.
11-10 21:11
Pivotal Phase 2 Rezatapopt PYNNACLE Data to Be Featured in Late-Breaking Oral Presentation at ENA 2026
PMV Pharmaceuticals announced updated results from the pivotal Phase 2 portion of the PYNNACLE trial for rezatapopt, a p53 reactivator, will be presented at the 38th EORTC-NCI-AACR Symposium on November 20, 2026. The presentation will include efficacy, molecular activity, and safety data from all trial cohorts. Rezatapopt targets TP53 Y220C mutations in advanced solid tumors and has received FDA Fast Track and Orphan Drug Designations. The Phase ...
11-04 13:00
PMV Pharmaceuticals Appoints Matt Eckler, Ph.D., to Board of Directors
PMV Pharmaceuticals announced the appointment of Dr. Matt Eckler to its Board of Directors. With over two decades of experience in healthcare investing and scientific research, Dr. Eckler will contribute strategic insights as the company prepares to submit an NDA for rezatapopt in 2027. Rezatapopt, a first-in-class p53 reactivator, targets the Y220C mutation in ovarian cancer and has received FDA Fast Track and Orphan Drug Designations. Dr. Eckle...
10-05 12:00
PMV Pharmaceuticals Appoints Philip Herman as Chief Commercial Officer
PMV Pharmaceuticals appoints Philip Herman as Chief Commercial Officer to lead commercial strategy and launch preparation for rezatapopt, a first-in-class p53 reactivator. The company plans to submit an NDA for accelerated approval of rezatapopt in platinum-resistant/refractory ovarian cancer patients in Q1 2027. Herman brings over 24 years of experience in oncology and rare disease therapies, previously leading launches at Repare Therapeutics an...
09-08 12:00
PMV Pharma Raises $50.8 Million to Fuel Cancer Drug Push
PMV Pharmaceuticals Inc. (NASDAQ:PMVP) on Monday shared interim data from its Phase 2 PYNNACLE trial for rezatapopt, an investigational treatment for ovarian cancer. Based on this data, the company announced its plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (F...
09-01 21:01
PMV Pharma prices $50M IPO at $1.21 per share
PMV Pharmaceuticals (PMVP) priced an oversubscribed public offering expected to raise about $50.8M in gross proceeds. The offering includes 22.055M shares of common stock and pre-funded warrants to pu...
09-01 16:47
PMV Pharmaceuticals shares are trading lower after the company announced the commencement of an underwritten public offering.
PMV Pharmaceuticals shares are trading lower after the company announced the commencement of an underwritten public offering.
09-01 04:21
PMV Pharma announces proposed public offering
PMV Pharmaceuticals (PMVP) said on Monday it launched an underwritten public offering of common stock and accompanying warrants. The company may also offer pre-funded warrants to certain investors in...
09-01 04:08
PMV Pharma Announces Proposed Public Offering of Securities
PMV Pharmaceuticals announced the commencement of an underwritten public offering of its common stock, warrants, and pre-funded warrants. TD Cowen is the sole book-running manager. The offering is subject to market conditions and SEC registration. The securities are being offered under a shelf registration statement on Form S-3 (Registration No. 333-283349). A preliminary prospectus supplement will be filed with the SEC. This press release does n...
08-31 20:02
PMV Pharmaceuticals Announces Updated Promising Rezatapopt Monotherapy Interim Ovarian Cancer Data From PYNNACLE Phase 2 Pivotal Trial
PMV Pharmaceuticals announced interim data from the Phase 2 PYNNACLE trial for rezatapopt in ovarian cancer patients with TP53 Y220C mutations. The trial showed a 46% overall response rate (ORR) with a median duration of response of 10.0 months. Rezatapopt demonstrated a favorable safety profile, with mostly Grade 1 and 2 treatment-related adverse events. The company received FDA feedback supporting its NDA submission strategy for accelerated app...
08-31 20:01
